Equillium (EQ)

About Equillium (EQ)

Equillium, Inc. is a clinical-stage biotechnology company that engages in the development of novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. Its product pipeline includes EQ001, which is a monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. The company was founded by Daniel Mark Bradbury, Bruce D. Steel, and Stephen Connelly in March 2017 and is headquartered in La Jolla, CA.

Details

Daily high

$1.24

Daily low

$1.10

Price at open

$1.11

52 Week High

$2.35

52 Week Low

$0.27

Market cap

74.3M

Dividend yield

0.00%

Volume

806,269

Avg. volume

469,598

P/E ratio

-1.93

Equillium News